Identification of an HIV-1 replication inhibitor which rescues host restriction factor APOBEC3G in Vif-APOBEC3G complex.

@article{Zhang2015IdentificationOA,
  title={Identification of an HIV-1 replication inhibitor which rescues host restriction factor APOBEC3G in Vif-APOBEC3G complex.},
  author={Shaoyan Zhang and L. Zhong and B. Chen and T. Pan and Xue Zhang and Liting Liang and Qianwen Li and Ziying Zhang and H. Chen and Jie Zhou and Hai-hua Luo and Hui Zhang and C. Bai},
  journal={Antiviral research},
  year={2015},
  volume={122},
  pages={
          20-7
        }
}
HIV-1 Vif protein is one of the most crucial accessory proteins for viral replication. It efficiently counteracts the important host restriction factor APOBEC3G (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G, A3G) which is lethal to HIV-1 by causing G to A mutation of viral genome. Vif protein mediates degradation of APOBEC3G via the complicated protein-protein interactions of Vif, APOBEC3G, Elongin C/B and Cullin 5. The importance of Vif-APOBEC3G complex makes it a good… Expand
A novel HIV-1 inhibitor that blocks viral replication and rescues APOBEC3s by interrupting vif/CBFβ interaction
  • Sizhu Duan, Shiqi Wang, +9 authors Xianghui Yu
  • Medicine, Chemistry
  • The Journal of Biological Chemistry
  • 2020
TLDR
It is demonstrated that CV-3 can effectively inhibit HIV-1 by blocking the interaction between Vif and CBFβ and that this interaction can serve as a new target for developing HIV- 1 inhibitors. Expand
Moloney leukemia virus 10 (MOV10) inhibits the degradation of APOBEC3G through interference with the Vif-mediated ubiquitin–proteasome pathway
TLDR
The results demonstrate a novel mechanism involved in the anti-HIV-1 function of MOV10, and suggest that both MOV10 and A3G belong to the interferon antiviral system, and may play complicated roles in antiviral functions. Expand
Identification of small molecule compounds targeting the interaction of HIV-1 Vif and human APOBEC3G by virtual screening and biological evaluation
TLDR
This study performs virtual screening to discover small molecule inhibitors that target the binding interface of the Vif/hA3G complex and demonstrates the feasibility of inhibiting HIV replication by abrogating the V if-hA 3G interaction with small molecules. Expand
Novel host restriction factors implicated in HIV-1 replication.
TLDR
Six novel restriction factors were discovered that exhibit significant antiviral activity: endoplasmic reticulum α1,2-mannosidase I (ERManI), translocator protein (TSPO), guanylate-binding protein 5 (GBP5), serine incorporator (SERINC3/5) and zinc-finger antiviral protein (ZAP). Expand
Fab-based inhibitors reveal ubiquitin independent functions for HIV Vif neutralization of APOBEC3 restriction factors
TLDR
It is established that Vif can neutralize A3 family members in a degradation-independent manner and illuminates how Vif uses a multi-pronged approach involving both degradation dependent and independent mechanisms to suppress A3 innate immunity. Expand
Multifaceted HIV‐1 Vif interactions with human E3 ubiquitin ligase and APOBEC3s
TLDR
The structural features of the recently determined structure of human A3F in complex with HIV‐1 Vif and its cofactor CBFβ are reviewed, insights into the molecular principles of Vif‐A3 interplay during the arms race between the virus and host are discussed, and therapeutic implications are highlighted. Expand
A New Class of Antiretroviral Enabling Innate Immunity by Protecting APOBEC3 from HIV Vif-Dependent Degradation.
TLDR
The current state of development of Vif inhibitors is examined, which are believed to have therapeutic and functional cure potential and these are described here as a potential platform for novel antiviral drug discovery. Expand
Anti-HIV Factors: Targeting Each Step of HIV's Replication Cycle.
TLDR
By better understanding how HIV hijacks the cellular machinery for its own benefit in completing its life-cycle, and how the virus adapts to circumvent the authors' intrinsic immunity, the field will be better equipped to design compounds that specifically interrupt virus replication and spread. Expand
Identification of a novel compound targeting the nuclear export of influenza A virus nucleoprotein
TLDR
ZBMD‐1 inhibited the replication of H1N1 and H3N2 influenza A virus strains in vitro, with an IC50 ranging from 0.41–1.14 μM, and inhibited the polymerase activity and specifically impaired the nuclear export of NP. Expand
Interruption of Vif/Elongin C interaction: In silico and experimental elucidation of the underlying molecular mechanism of benzimidazole-based APOBEC3G stabilizers.
TLDR
An exhaustive in silico workflow by which the capacity of MM-1 to interrupt Vif/Elongin C interaction was tested was confirmed, showing the potential of molecular modelling to address issues related to drug development. Expand
...
1
2
...

References

SHOWING 1-10 OF 34 REFERENCES
HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.
TLDR
It is shown how the bimodal translational and posttranslational inhibitory effects of Vif on APOBEC3G combine to markedly suppress the expression of this potent antiviral enzyme in virally infected cells, thereby effectively curtailing the incorporation of APOBec3G into newly formed HIV-1 virions. Expand
Small-Molecule Inhibition of Human Immunodeficiency Virus Type 1 Replication by Targeting the Interaction between Vif and ElonginC
TLDR
Findings support the notion that suppressing Vif function can liberate A3G to carry out its antiviral activity and demonstrate that regulation of the Vif-ElonginC interaction is a novel target for small-molecule inhibitors of HIV-1. Expand
Species-Specific Exclusion of APOBEC3G from HIV-1 Virions by Vif
TLDR
It is reported that HIV-1 Vif forms a complex with human APOBEC3G that prevents its virion encapsidation and suggests that therapeutic intervention that either induced APOBec3G or blocked its interaction with Vif could be clinically beneficial. Expand
HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation
TLDR
Evidence is described that Vif binds APOBEC3G and induces its rapid degradation, thus eliminating it from cells and preventing its incorporation into HIV-1 virions, providing promising approaches for drug discovery. Expand
Small-molecule inhibition of HIV-1 Vif
TLDR
This work identifies a small molecule, RN-18, that antagonizes Vif function and inhibits HIV-1 replication only in the presence of A3G, and enhances Vif degradation only in a Vif-dependent manner and reduces viral infectivity by increasing A 3G incorporation into virions and enhances cytidine deamination of the viral genome. Expand
Vif Overcomes the Innate Antiviral Activity of APOBEC3G by Promoting Its Degradation in the Ubiquitin-Proteasome Pathway*
TLDR
It is reported here that Vif counteracts the antiviral activity of APOBEC3G by targeting it for destruction by the ubiquitin-proteasome pathway and implicate the proteasome as a site of dynamic interplay between microbial and cellular defenses. Expand
T-cell differentiation factor CBF-β regulates HIV-1 Vif-mediated evasion of host restriction
TLDR
It is demonstrated in human T cells that core binding factor β (CBF-β) is a key regulator of the evasion of HIV-1 from the host defence mediated by APOBEC3, and is a unique regulator of primate lentiviral Vif. Expand
The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif
TLDR
It is shown that the HIV-1 virion infectivity factor (Vif) protein protects the virus from APOBEC3G-mediated inactivation by preventing its incorporation into progeny virions, thus allowing the ensuing infection to proceed without DNA deamination. Expand
Induction of APOBEC3G Ubiquitination and Degradation by an HIV-1 Vif-Cul5-SCF Complex
  • Xianghui Yu, Yunkai Yu, +4 authors Xiao-Fang Yu
  • Biology, Medicine
  • Science
  • 2003
TLDR
The results indicate that the conserved Cul5-SCF pathway used by Vif is a potential target for antiviral development. Expand
Small Molecular Compounds Inhibit HIV-1 Replication through Specifically Stabilizing APOBEC3G*
TLDR
IMB-26 and IMB-35 are novel anti-HIV leads working through specific stabilization of hA3G, a host inhibitor for human immunodeficiency virus, type 1, that is protected from Vif-mediated degradation. Expand
...
1
2
3
4
...